Psychedelics

MindMed joins the Clinical Trials Transformation Initiative, a forward-looking healthcare association that develops/promotes new health therapies.

TSI EDITOR | 2021-10-13

Novamind's new DEA licenses open up opportunities to host formal clinical trials.

TSI EDITOR | 2021-10-13

PharmaTher receives its second FDA orphan drug designation for a ketamine-based therapy.

TSI EDITOR | 2021-10-13

Cybin files a new patent application in support of the development of drug candidate CYB004.

TSI EDITOR | 2021-10-12

Numinus announces expansion of its psychedelics research facility and an application to Health Canada for a second Dealer's License.

TSI EDITOR | 2021-10-08

Novamind is expanding its mental health care to include the treatment of patients with palliative needs, via its new Murray, Utah treatment clinic.

TSI EDITOR | 2021-10-07

Psychedelic drugs like psilocybin, LSD and MDMA have amazing medicinal and commercial potential. So does ketamine, but ketamine is already legal.

TSI EDITOR | 2021-10-07

PharmaTher initiates a Phase 2a clinical trial for a ketamine-based therapy for Parkinson's Disease, expected to commence in October 2021.

TSI EDITOR | 2021-10-06

Levitee Labs reports (unaudited) revenues of CAD$893,863 for the month of August from clinic operations.

TSI EDITOR | 2021-10-05

Optimi Health files a provisional patent application for a stable extraction method for natural psilocybin.

TSI EDITOR | 2021-10-05

NEW BULL MARKET ALERT

Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry

Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now